Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Key Points: EPZ-5676 is a potent DOT1L inhibitor that causes tumor regressions in a rat xenograft model of MLL-rearranged leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“DOT1L drives the expression of genes associated with epithelial-mesenchymal transition (EMT) in breast cancer [79] and is also a key regulator of hematopoiesis [80], making it a therapeutic target in MLL-rearranged leukemias [81].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Self-citationMLL translocations, histone modifications and leukaemia stem-cell development
Krivtsov, A. V., & Armstrong, S. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2253 · Cited by 1,249 · cited 2×
“Rearrangements in the MLL gene at position 11q23 occur in 5% to 10% of acute leukemias of lymphoid, myeloid, or mixed/ indeterminant lineage and are especially common in infant acute leukemias and in secondary acute myeloid leukemias arising in patients following treatment of other malignancies with topoisomerase II i…”
BackgroundInfluentialA Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122 · cited 1×
“Similar lag phases in recovery of intracellular protein phosphorylation have been observed with kinase inhibitors of long residence time.(44) These results suggest that reduced global H3K79 methylation can be used as a pharmacodynamic readout for DOT1L inhibitor activity in vivo, but that there is likely to be a lag t…”
BackgroundCopeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationMLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters
Milne, T. A., Briggs, S. D., Brock, H. W., Martin, M. E., Gibbs, D., Allis, C. D., & Hess, J. L. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00741-4 · Cited by 1,053 · cited 2×
“The MLL gene encodes a large multidomain protein (MLL) that regulates transcription of developmental genes including the HOX genes.1 The amino terminal portion of the protein contains regions that target MLL to DNA directly, whereas the carboxyl terminal portion of the protein contains a Su(Var)3-9, Enhancer of zeste…”
BackgroundSelective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923 · cited 10×
“Proliferation assays and IC50 value determinations were performed as described previously.(30) Cell-cycle analysis and Annexin staining.”
BackgroundMethodSelf-citationMLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870 · cited 14×
“The MLL gene encodes a large multidomain protein (MLL) that regulates transcription of developmental genes including the HOX genes.1 The amino terminal portion of the protein contains regions that target MLL to DNA directly, whereas the carboxyl terminal portion of the protein contains a Su(Var)3-9, Enhancer of zeste…”
BackgroundMethodResultSelf-citationMethylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain
Feng, Q., Wang, H., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Struhl, K., & Zhang, Y. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00901-6 · Cited by 865 · cited 1×
“DOT1L is a histone methyltransferase enzyme that targets lysine 79 in the globular domain of histone H3 (H3K79) for mono-, di-, or trimethylation (H3K79me1, me2, or me3).(19,20) As a result, MLLfusion proteins gain the ability to recruit DOT1L to MLL target genes where the resulting hypermethylation at H3K79 leads to…”
BackgroundThe Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840 · cited 1×
“The enzyme inhibition constant (Ki) value for EPZ5676 was determined by fitting inhibition data to the Morrison quadratic equation.(34) Residence times for EPZ-5676 and EPZ004777 were calculated as the reciprocal of the enzymatic-ligand dissociation rate, determined by surface plasmon resonance using methods described…”
MethodhDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804 · cited 3×
“As a result, MLLfusion proteins gain the ability to recruit DOT1L to MLL target genes where the resulting hypermethylation at H3K79 leads to aberrant expression of a characteristic set of genes including HOXA9 and MEIS1 that drive leukemogenesis.(14,15,21-27) Several recent studies have used genetic ablation or small…”
Background
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
“These leukemias are especially vulnerable to genetic and chemical perturbation of DOT1L, and DOT1L inhibitors are now in clinical trials for these malignancies (Daigle et al., 2013).”
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“By occupying the SAMbinding pocket and inducing conformational changes in DOT1L, EPZ-5676, a derivative of EPZ004777, is another effective DOT1L inhibitor that led to tumor regression in rat xenograft models of MLL-rearranged leukemia (Daigle et al., 2013).”
BackgroundInfluential
Metadata
- Authors
- Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., Waters, N. J., Chesworth, R., Moyer, M. P., Copeland, R. A., Richon, V. M., & Pollock, R. M.
- Affiliations
- Epizyme (United States) (US)
- Epizyme, Inc., Cambridge, MA
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-08-08
- Volume
- 122
- Issue
- 6
- Pages
- 1017-1025
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3739029
- OpenAlex
- W2104954848
- Cited by
- 722
- References
- 45
- Citations by year
- 2026: 19 · 2025: 37 · 2024: 36 · 2023: 45 · 2022: 54 · 2021: 53 · 2020: 57 · 2019: 72 · 2018: 52 · 2017: 81 · 2016: 62 · 2015: 78 · 2014: 65 · 2013: 8
- FWCI
- 52.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- DOT1L, histone methyltransferase inhibition, H3K79 methylation, acute leukemia, MLL translocation, small molecule inhibitors, targeted therapy
- MeSH terms
- Histone Methyltransferases, Animals, Antineoplastic Agents, Benzimidazoles, Dose-Response Relationship, Drug, Female, Histones, Humans, Leukemia, Methyltransferases, Neoplasm Transplantation, Protein Conformation, Histone-Lysine N-Methyltransferase, Rats, Nude, DNA Methylation, Cell Line, Tumor, Cell Proliferation, Rats, Myeloid-Lymphoid Leukemia Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. https://app.cochat.ai/papers/10.1182/blood-2013-04-497644
- The paper
- Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., Waters, N. J., Chesworth, R., Moyer, M. P., Copeland, R. A., Richon, V. M., & Pollock, R. M. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. https://doi.org/10.1182/blood-2013-04-497644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.